Cargando…

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS-CoV-2 are an option for drug development for treating COVID-19. Here, we report the identification and characterization of two g...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chao, Wang, Yifan, Zhu, Yuanfei, Liu, Caixuan, Gu, Chenjian, Xu, Shiqi, Wang, Yalei, Zhou, Yu, Wang, Yanxing, Han, Wenyu, Hong, Xiaoyu, Yang, Yong, Zhang, Xueyang, Wang, Tingfeng, Xu, Cong, Hong, Qin, Wang, Shutian, Zhao, Qiaoyu, Qiao, Weihua, Zang, Jinkai, Kong, Liangliang, Wang, Fangfang, Wang, Haikun, Qu, Di, Lavillette, Dimitri, Tang, Hong, Deng, Qiang, Xie, Youhua, Cong, Yao, Huang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801428/
https://www.ncbi.nlm.nih.gov/pubmed/33431876
http://dx.doi.org/10.1038/s41467-020-20465-w
_version_ 1783635572659585024
author Zhang, Chao
Wang, Yifan
Zhu, Yuanfei
Liu, Caixuan
Gu, Chenjian
Xu, Shiqi
Wang, Yalei
Zhou, Yu
Wang, Yanxing
Han, Wenyu
Hong, Xiaoyu
Yang, Yong
Zhang, Xueyang
Wang, Tingfeng
Xu, Cong
Hong, Qin
Wang, Shutian
Zhao, Qiaoyu
Qiao, Weihua
Zang, Jinkai
Kong, Liangliang
Wang, Fangfang
Wang, Haikun
Qu, Di
Lavillette, Dimitri
Tang, Hong
Deng, Qiang
Xie, Youhua
Cong, Yao
Huang, Zhong
author_facet Zhang, Chao
Wang, Yifan
Zhu, Yuanfei
Liu, Caixuan
Gu, Chenjian
Xu, Shiqi
Wang, Yalei
Zhou, Yu
Wang, Yanxing
Han, Wenyu
Hong, Xiaoyu
Yang, Yong
Zhang, Xueyang
Wang, Tingfeng
Xu, Cong
Hong, Qin
Wang, Shutian
Zhao, Qiaoyu
Qiao, Weihua
Zang, Jinkai
Kong, Liangliang
Wang, Fangfang
Wang, Haikun
Qu, Di
Lavillette, Dimitri
Tang, Hong
Deng, Qiang
Xie, Youhua
Cong, Yao
Huang, Zhong
author_sort Zhang, Chao
collection PubMed
description The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS-CoV-2 are an option for drug development for treating COVID-19. Here, we report the identification and characterization of two groups of mouse neutralizing monoclonal antibodies (MAbs) targeting the receptor-binding domain (RBD) on the SARS-CoV-2 spike (S) protein. MAbs 2H2 and 3C1, representing the two antibody groups, respectively, bind distinct epitopes and are compatible in formulating a noncompeting antibody cocktail. A humanized version of the 2H2/3C1 cocktail is found to potently neutralize authentic SARS-CoV-2 infection in vitro with half inhibitory concentration (IC50) of 12 ng/mL and effectively treat SARS-CoV-2-infected mice even when administered at as late as 24 h post-infection. We determine an ensemble of cryo-EM structures of 2H2 or 3C1 Fab in complex with the S trimer up to 3.8 Å resolution, revealing the conformational space of the antigen–antibody complexes and MAb-triggered stepwise allosteric rearrangements of the S trimer, delineating a previously uncharacterized dynamic process of coordinated binding of neutralizing antibodies to the trimeric S protein. Our findings provide important information for the development of MAb-based drugs for preventing and treating SARS-CoV-2 infections.
format Online
Article
Text
id pubmed-7801428
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78014282021-01-21 Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections Zhang, Chao Wang, Yifan Zhu, Yuanfei Liu, Caixuan Gu, Chenjian Xu, Shiqi Wang, Yalei Zhou, Yu Wang, Yanxing Han, Wenyu Hong, Xiaoyu Yang, Yong Zhang, Xueyang Wang, Tingfeng Xu, Cong Hong, Qin Wang, Shutian Zhao, Qiaoyu Qiao, Weihua Zang, Jinkai Kong, Liangliang Wang, Fangfang Wang, Haikun Qu, Di Lavillette, Dimitri Tang, Hong Deng, Qiang Xie, Youhua Cong, Yao Huang, Zhong Nat Commun Article The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS-CoV-2 are an option for drug development for treating COVID-19. Here, we report the identification and characterization of two groups of mouse neutralizing monoclonal antibodies (MAbs) targeting the receptor-binding domain (RBD) on the SARS-CoV-2 spike (S) protein. MAbs 2H2 and 3C1, representing the two antibody groups, respectively, bind distinct epitopes and are compatible in formulating a noncompeting antibody cocktail. A humanized version of the 2H2/3C1 cocktail is found to potently neutralize authentic SARS-CoV-2 infection in vitro with half inhibitory concentration (IC50) of 12 ng/mL and effectively treat SARS-CoV-2-infected mice even when administered at as late as 24 h post-infection. We determine an ensemble of cryo-EM structures of 2H2 or 3C1 Fab in complex with the S trimer up to 3.8 Å resolution, revealing the conformational space of the antigen–antibody complexes and MAb-triggered stepwise allosteric rearrangements of the S trimer, delineating a previously uncharacterized dynamic process of coordinated binding of neutralizing antibodies to the trimeric S protein. Our findings provide important information for the development of MAb-based drugs for preventing and treating SARS-CoV-2 infections. Nature Publishing Group UK 2021-01-11 /pmc/articles/PMC7801428/ /pubmed/33431876 http://dx.doi.org/10.1038/s41467-020-20465-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zhang, Chao
Wang, Yifan
Zhu, Yuanfei
Liu, Caixuan
Gu, Chenjian
Xu, Shiqi
Wang, Yalei
Zhou, Yu
Wang, Yanxing
Han, Wenyu
Hong, Xiaoyu
Yang, Yong
Zhang, Xueyang
Wang, Tingfeng
Xu, Cong
Hong, Qin
Wang, Shutian
Zhao, Qiaoyu
Qiao, Weihua
Zang, Jinkai
Kong, Liangliang
Wang, Fangfang
Wang, Haikun
Qu, Di
Lavillette, Dimitri
Tang, Hong
Deng, Qiang
Xie, Youhua
Cong, Yao
Huang, Zhong
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
title Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
title_full Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
title_fullStr Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
title_full_unstemmed Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
title_short Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
title_sort development and structural basis of a two-mab cocktail for treating sars-cov-2 infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801428/
https://www.ncbi.nlm.nih.gov/pubmed/33431876
http://dx.doi.org/10.1038/s41467-020-20465-w
work_keys_str_mv AT zhangchao developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT wangyifan developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT zhuyuanfei developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT liucaixuan developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT guchenjian developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT xushiqi developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT wangyalei developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT zhouyu developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT wangyanxing developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT hanwenyu developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT hongxiaoyu developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT yangyong developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT zhangxueyang developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT wangtingfeng developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT xucong developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT hongqin developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT wangshutian developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT zhaoqiaoyu developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT qiaoweihua developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT zangjinkai developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT kongliangliang developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT wangfangfang developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT wanghaikun developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT qudi developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT lavillettedimitri developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT tanghong developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT dengqiang developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT xieyouhua developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT congyao developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections
AT huangzhong developmentandstructuralbasisofatwomabcocktailfortreatingsarscov2infections